ReviewJournal of family medicine and primary care2025
The role of epigenetics in cancer: From pathways to the clinic.
Review in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioengineered systems to exploit tumor microenvironment metabolism.Trends in cancer · 2026Review
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape.Molecular cancer · 2026Review
- Hypoxic adaptation theory of cancer.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic changes are inherited but repairable genetic DNA modifications that affect gene expression regardless of the underlying sequence. Epigenetic abnormalities have been associated with a wide range of human diseases, including cancer. Malignancy can be caused by abnormal epigenetic changes that incorrectly activate oncogenes. Epigenetic marks are appealing therapeutic targets because they are reversible and susceptible to exogenous changes. Significant progress has been made in developing treatments that target epigenetic regulation in the past few years, with several pharmaceuticals being evaluated. this review describes the epigenetic drugs currently undergoing clinical trials. It also discusses the pros and cons of using them to treat cancer and the role of epigenetics in cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.